$0.0667
At close: Apr 17, 3:55 PM EDT
Comments
Loading...
Kane Biotech Analyst Ratings and Price Targets | OTC:KNBIF | Benzinga
Kane Biotech Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Kane Biotech Corp from these most-recent analyst ratings.
Analyst Ratings for Kane Biotech
| Buy Now | Get Alert | ||||||||
|---|---|---|---|---|---|---|---|---|---|
No data available to display | |||||||||
FAQ
What is the target price for Kane Biotech (KNBIF) stock?
There is no price target for Kane Biotech
What is the most recent analyst rating for Kane Biotech (KNBIF)?
There is no analyst for Kane Biotech
When was the last upgrade for Kane Biotech (KNBIF)?
There is no last upgrade for Kane Biotech
When was the last downgrade for Kane Biotech (KNBIF)?
There is no last downgrade for Kane Biotech.
When is the next analyst rating going to be posted or updated for Kane Biotech (KNBIF)?
There is no next analyst rating for Kane Biotech.
Is the Analyst Rating Kane Biotech (KNBIF) correct?
There is no next analyst rating for Kane Biotech.
Browse analyst ratings and price targets on all stocks.
